Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Patnaik MM, et al. Among authors: odenike o. Leukemia. 2022 Dec;36(12):2934-2938. doi: 10.1038/s41375-022-01754-3. Epub 2022 Nov 5. Leukemia. 2022. PMID: 36335264 No abstract available.
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Talpaz M, et al. Among authors: odenike o, o neill p. J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81. J Hematol Oncol. 2013. PMID: 24283202 Free PMC article. Clinical Trial.
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. Christian S, et al. Among authors: odenike o. Am J Hematol. 2020 Aug;95(8):937-943. doi: 10.1002/ajh.25838. Epub 2020 May 8. Am J Hematol. 2020. PMID: 32311140 Free PMC article.
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Fan Y, et al. Among authors: odenike o. Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 30622841 Free PMC article.
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien K. Artz AS, et al. Among authors: odenike o. Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64. doi: 10.1016/j.bbmt.2006.05.015. Biol Blood Marrow Transplant. 2006. PMID: 16920562 Free article. Clinical Trial.
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.
Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. Liu H, et al. Among authors: odenike o. Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018. Exp Hematol Oncol. 2018. PMID: 29344432 Free PMC article.
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W. Odenike O, et al. Invest New Drugs. 2015 Apr;33(2):371-9. doi: 10.1007/s10637-014-0194-2. Epub 2014 Dec 9. Invest New Drugs. 2015. PMID: 25483416 Free PMC article. Clinical Trial.
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Jain N, et al. Among authors: odenike o. Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31. Clin Cancer Res. 2014. PMID: 24178622 Free PMC article. Clinical Trial.
126 results